Understanding the genetics of poor outcome neuroblastoma to improve treatment
A genome wide study of unresectable, MYCN non-amplied, unfavourable histology neuroblastomas in patients older than 18 months of age
Investigating the makeup of malignant rhabdoid tumours
RNA‐sequencing to characterise malignant rhabdoid tumour heterogeneity: a pilot study in archival frozen material
Can we identify an 'ultra-high-risk' type of neuroblastoma?
A pilot study of expression profiling using RNAseq from formalin fixed neuroblastoma and paired diagnostic and relapsed frozen neuroblastomas.
Understanding the molecular makeup of low grade glioma and DIPG
Molecular pathophysiology of histone G34R mutated childhood brain tumours: towards the development of novel targeted therapies
Using genetics to find targets for new drugs to treat relapsed neuroblastoma
Characterisation and validation of recurrently mutated genes in relapsed neuroblastoma as targets for novel therapies
Using the immune system to improve treatment for Hodgkin lymphoma
Targeting GPNMB in Hodgkin lymphoma
Understanding the order of genetic changes that lead to Wilms tumour to improve treatment
Ordering of driver mutations in bilateral Wilms’ tumour
Understanding the biology of malignant rhabdoid tumours to develop targeted treatments
Improved therapeutic targeting in malignant rhabdoid tumours using discovery proteomics analysis
Improving our understanding of ependymomas in the spinal cord
Comprehensive molecular characterization of paediatric spinal ependymomas